XML 82 R51.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Major Customers and Concentration of Credit Risk (Details) (USD $) | 12 Months Ended
--- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012
Concentration Risk [Line Items] |  |  |
Revenue | $ 10,456,766 us-gaap_SalesRevenueNet | $ 13,467,346 us-gaap_SalesRevenueNet | $ 4,118,652 us-gaap_SalesRevenueNet
Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 100.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember | 100.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember | 100.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember
Roche |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | 7,357,346 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember | 9,181,759 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember | 0 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember
Accounts receivable | 2,300,000 us-gaap_AccountsReceivableNet / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember | 2,600,000 us-gaap_AccountsReceivableNet / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember |
Roche | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 70.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember | 68.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember | 0.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember
Roche | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 82.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember | 79.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_HoffmanLaRocheMember |
NIAID |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | 1,229,084 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_NiaidMember | 2,090,939 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_NiaidMember | 2,831,115 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_NiaidMember
Accounts receivable | 190,000 us-gaap_AccountsReceivableNet / us-gaap_MajorCustomersAxis = ino_NiaidMember | 382,000 us-gaap_AccountsReceivableNet / us-gaap_MajorCustomersAxis = ino_NiaidMember |
NIAID | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 12.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NiaidMember | 16.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NiaidMember | 69.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NiaidMember
NIAID | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 7.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NiaidMember | 12.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = us-gaap_AccountsReceivableMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NiaidMember |
GeneOne (affiliated entity) |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | 479,464 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_VgxInternationalMember | 425,000 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_VgxInternationalMember | 577,467 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_VgxInternationalMember
GeneOne (affiliated entity) | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 5.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_VgxInternationalMember | 3.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_VgxInternationalMember | 14.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_VgxInternationalMember
NIH Research Project Grant |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | 694,457 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_NIHResearchProjectGrantMember | 152,499 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_NIHResearchProjectGrantMember | 0 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_NIHResearchProjectGrantMember
NIH Research Project Grant | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 6.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NIHResearchProjectGrantMember | 1.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NIHResearchProjectGrantMember | 0.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_NIHResearchProjectGrantMember
All other |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 696,415 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_AllOtherCustomersMember | $ 1,617,149 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_AllOtherCustomersMember | $ 710,070 us-gaap_SalesRevenueNet / us-gaap_MajorCustomersAxis = ino_AllOtherCustomersMember
All other | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 7.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_AllOtherCustomersMember | 12.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_AllOtherCustomersMember | 17.00%us-gaap_ConcentrationRiskPercentage1 / us-gaap_ConcentrationRiskByBenchmarkAxis = ino_RevenueMember / us-gaap_ConcentrationRiskByTypeAxis = us-gaap_CustomerConcentrationRiskMember / us-gaap_MajorCustomersAxis = ino_AllOtherCustomersMember

X
- Definition For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.9) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.5) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=ino_RevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_AllOtherCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_HoffmanLaRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_NiaidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_NIHResearchProjectGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_VgxInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |